title: FDG PET/CT in the management of primary pleural tumors and pleural metastases.
abstract: OBJECTIVE. FDG PET/CT is emerging as an important modality in the evaluation of pleural tumors. PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma. This modality has distinct advantages in characterizing other primary pleural tumors and pleural metastases. CONCLUSION. FDG PET/CT is a useful imaging modality in the management of patients with primary pleural tumors and pleural metastases.
authors.affiliation: Russel H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, 601 N Caroline St / JHOC 3235, Baltimore, MD 21287, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Kruse
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Sherry
authors.forename: Vasavi
authors.initials: V
authors.lastname: Paidpally
authors.forename: Gustavo
authors.initials: G
authors.lastname: Mercier
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis; D008654:Mesothelioma / Q000000981:diagnostic imaging / Q000473:pathology; D064847:Multimodal Imaging; D009361:Neoplasm Invasiveness / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D047368:Tumor Burden
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18